查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1951226

冷凍乾燥注射劑市場－全球產業規模、佔有率、趨勢、機會與預測：包裝、劑量、適應症、終端用戶、地區和競爭格局，2021-2031年

Lyophilized Injectable Market - Global Industry Size, Share, Trends, Opportunity, & Forecast Segmented By Packaging, By Delivery, By Indication, By End-User, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球冷凍乾燥注射劑市場預計將從 2025 年的 33.7 億美元成長到 2031 年的 58.5 億美元，複合年成長率為 9.63%。

冷凍乾燥注射劑是一種冷凍乾燥製劑，可透過去除水分來提高對溫度敏感的生物製藥的穩定性並延長其保存期限。市場成長趨勢主要受以下因素驅動：全球範圍內需要生物製劑治療的慢性疾病發生率不斷上升，以及藥品分銷網路對長期儲存能力的迫切需求。此外，越來越多的複雜分子在液態下穩定性較差，也迫使生產商採用冷凍乾燥技術來確保藥物在運輸過程中的效力。

市場概覽
預測期 2027-2031
市場規模：2025年 33.7億美元
市場規模：2031年 58.5億美元
複合年成長率：2026-2031年 9.63%
成長最快的細分市場 代謝性疾病
最大的市場 北美洲

然而，該市場面臨許多挑戰，包括生產流程複雜和供應鏈不穩定，這常常導致嚴重的藥品短缺。無菌生產設施所需的大量資本投入以及對監管標準的嚴格遵守進一步限制了產能。根據美國藥典（USP）2024年的數據，無菌注射劑佔所有活性成分短缺的69%。這一數字凸顯了生產基礎設施的嚴重不足，並對全球市場的穩定成長構成了重大障礙。

市場促進因素

生物製藥和複雜大分子療法的快速發展是市場成長的關鍵驅動力。隨著製藥創新者日益重視單株抗體和胜肽等大分子藥物，這些液體製劑固有的不穩定性使得冷凍乾燥技術的應用成為維持其長期療效的必要手段。這些治療方法獲得監管部門核准的數量持續成長，也印證了這一發展勢頭。例如，BioPharma PEG在2025年1月報道稱，FDA在2024年核准了18種新的生物製藥，這在通常需要先進凍乾技術的創新治療方法中佔有相當大的比例。此外，業界對專科治療的日益關注也推動了這一轉變。監管事務專業人員協會（RAPS）在2025年1月指出，2024年新藥認證中有52%用於治療罕見疾病，而罕見疾病領域高度依賴穩定的冷凍乾燥注射劑進行全球分銷。

同時，合約研發生產機構（CDMO）服務的成長正在改變製藥業的格局。由於無菌凍乾製程需要大量的資金投入和技術挑戰，創新企業擴大將生產外包給專業合作夥伴，而這些合作夥伴也正在積極擴建設施以避免產能瓶頸。根據DCAT價值鏈洞察2025年7月發布的報告，Better Pharma已在伊利諾伊州德斯普蘭斯市啟動了一座價值2.85億美元的新臨床生產設施的建設，以確保複雜注射劑的長期供應。這項增加的外部生產投資滿足了對適應性強、擴充性的供應鏈的迫切需求，直接緩解了無菌注射劑生產基礎設施長期以來的脆弱性。

市場挑戰

生產流程的高度複雜性和供應鏈固有的脆弱性是限制全球冷凍乾燥注射劑市場發展的主要障礙。建立無菌生產環境需要大量的資金投入和嚴格遵守監管通訊協定，這限制了合格生產商的數量。生產能力的集中化意味著，即使單一工廠出現輕微的技術問題或品質保證失誤，也可能導致大範圍的產品供不應求。這種缺乏營運柔軟性限制了該行業快速調整產量以應對需求波動的能力。

反覆出現的供應中斷直接降低了市場收入，並阻礙了冷凍乾燥療法的廣泛應用。持續無法維持可靠的庫存水準迫使醫療機構限制供應或轉向其他製劑。根據美國醫療保健系統藥劑師協會 (ASHP) 統計，2024 年第一季，製藥業的藥品短缺數量達到創紀錄的 323 種。這種前所未有的供應鏈不穩定性凸顯了製造商在滿足全球需求方面所面臨的挑戰，並嚴重阻礙因素了市場實現永續的財務成長。

市場趨勢

雙腔注射器和藥筒的廣泛應用代表包裝技術的重大進步，旨在緩解冷凍乾燥產品復溶過程中遇到的難題。這些先進的系統將冷凍乾燥粉末和稀釋劑分別置於獨立的腔室中，從而實現裝置內的自動混合，避免了人為操作失誤以及手動操作管瓶帶來的污染風險。這種對以患者為中心的設計的日益重視也體現在關鍵組件製造商強勁的財務表現上。根據Stevanato集團於2025年3月發布的2024會計年度財務報告，其高價值解決方案部門（包括高性能注射器）的營收達到4.223億歐元，較去年同期成長15%。

同時，人工智慧 (AI) 在循環最佳化中的應用正從根本上改變製造業的生產效率，它以預測模型取代了傳統的試驗法。製藥工程師正利用人工智慧演算法數位雙胞胎模擬來預測乾燥過程，並即時追蹤關鍵製程變量，從而在確保產品品質穩定的同時，顯著縮短高能耗的生產週期。領先的生物製藥公司正積極採用這些數位化工具來提升供應鏈的反應速度。例如，賽諾菲於 2025 年 5 月宣布推出第三個數位化加速器項目，致力於數位化。這些由人工智慧驅動的措施旨在將新藥上市時間縮短至多一年。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球凍乾注射劑市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依包裝方式（一次性管瓶、照護現場復溶、特殊包裝）
    • 依給藥方式（預填充稀釋劑注射器、專用複溶裝置、一步式裝置、多步驟裝置）
    • 按適應症（自體免疫疾病、感染疾病、代謝性疾病、其他）
    • 依最終用戶（醫院藥局、零售藥局、其他）分類
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章 北美冷凍乾燥注射劑市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

7. 歐洲冷凍乾燥注射劑市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

8. 亞太地區冷凍乾燥注射劑市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

9. 中東和非洲冷凍乾燥注射劑市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章 南美洲冷凍乾燥注射劑市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進要素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 最新進展

第13章 全球冷凍乾燥注射劑市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的可能性
  • 供應商電力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • B. Braun Melsungen AG
  • Baxter International Inc.
  • Becton, Dickinson and Company
  • Schott AG
  • Aristopharma Ltd.
  • Vetter Pharma GmbH
  • Jubilant HollisterStier LLC
  • F. Hoffmann-La Roche Ltd
  • Novo Nordisk A/S

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 16994

The Global Lyophilized Injectable Market is projected to expand from USD 3.37 Billion in 2025 to USD 5.85 Billion by 2031, reflecting a CAGR of 9.63%. Lyophilized injectables consist of freeze-dried pharmaceutical formulations developed to improve the stability and extend the shelf life of temperature-sensitive biological products by eliminating moisture content. The market's upward trajectory is largely fueled by the growing global incidence of chronic conditions that require biologic treatments, alongside the essential need for prolonged storage capacities within pharmaceutical distribution networks. Furthermore, the rising creation of complex molecules that lack stability in liquid states forces producers to implement lyophilization techniques to guarantee efficacy during transportation.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 3.37 Billion
Market Size 2031USD 5.85 Billion
CAGR 2026-20319.63%
Fastest Growing SegmentMetabolic Conditions
Largest MarketNorth America

Conversely, the market encounters substantial hurdles regarding production intricacy and supply chain instability, which frequently lead to severe product shortages. The necessity for significant capital expenditure on sterile manufacturing sites and strict adherence to regulatory standards further limits production potential. According to data from the U.S. Pharmacopeia in 2024, sterile injectable drugs accounted for 69% of all active drug shortages. This figure highlights the severe fragility of the manufacturing infrastructure, representing a significant barrier to the steady growth of the global market.

Market Driver

The swift expansion of biologics and complex macromolecule therapies acts as a major catalyst for market advancement. As pharmaceutical innovators increasingly prioritize large-molecule medications like monoclonal antibodies and peptides, the natural instability of these liquid formulations demands the application of lyophilization to maintain long-term potency. This momentum is supported by the consistent volume of regulatory approvals for such treatments; for instance, Biopharma PEG reported in January 2025 that the FDA authorized 18 new biologic entities in 2024, constituting a significant share of new therapies that usually necessitate sophisticated freeze-drying methods. This transition is further bolstered by the industry's emphasis on specialized medicine, with the Regulatory Affairs Professionals Society noting in January 2025 that 52% of new drug approvals in 2024 targeted rare diseases, a sector heavily dependent on stable, lyophilized injectable forms for worldwide distribution.

Simultaneously, the growth of Contract Development and Manufacturing Organization (CDMO) services is transforming the production environment. The substantial capital requirements and technical difficulties linked to sterile lyophilization are driving innovators to outsource production to specialized partners who are actively expanding their facilities to avoid capacity constraints. As reported by DCAT Value Chain Insights in July 2025, Vetter Pharma began construction on a new $285 million clinical manufacturing facility in Des Plaines, Illinois, aiming to ensure long-term availability for complex injectables. This increase in external manufacturing investment meets the urgent demand for adaptable and scalable supply chains, directly mitigating the historical vulnerability of the sterile injectable production base.

Market Challenge

The intense complexity of production processes and the inherent vulnerability of the supply chain serve as major obstacles to the advancement of the Global Lyophilized Injectable Market. Creating sterile manufacturing environments requires massive capital funding and rigorous compliance with regulatory protocols, which limits the pool of qualified manufacturers. This centralization of manufacturing capabilities implies that even slight technical issues or quality assurance failures at a single site can cause extensive product unavailability. Such operational inflexibility constrains the industry's capacity to rapidly adjust production levels in reaction to shifting demand.

These repeated supply disruptions directly diminish market earnings and impede the wider acceptance of lyophilized treatments. The ongoing failure to sustain dependable inventory levels compels healthcare networks to ration supplies or transition to substitute formulations. According to the American Society of Health-System Pharmacists, the pharmaceutical sector hit a record high of 323 active drug shortages in the first quarter of 2024. This unparalleled degree of supply chain volatility emphasizes the challenges manufacturers encounter in satisfying global requirements, thereby serving as a primary constraint on the market's consistent financial expansion.

Market Trends

The widespread adoption of dual-chamber syringes and cartridges marks a significant advancement in packaging technology, designed to alleviate the reconstitution difficulties associated with lyophilized products. These sophisticated systems separate the freeze-dried powder and the diluent into distinct chambers, enabling automatic mixing within the unit to eradicate user mistakes and contamination risks linked to manual vial manipulation. The increasing dependence on these patient-friendly designs is mirrored in the robust financial results of major component producers. As per the Stevanato Group's fiscal year 2024 results released in March 2025, revenue from their high-value solutions division, which comprises high-performance syringes, rose by 15% year-over-year to reach €422.3 million.

In parallel, the integration of Artificial Intelligence (AI) for cycle optimization is radically transforming manufacturing productivity by substituting empirical trial-and-error approaches with predictive modeling. Pharmaceutical engineers are utilizing AI algorithms and digital twin simulations to predict drying behaviors and track essential process variables in real-time, guaranteeing uniform product quality while significantly shortening energy-heavy cycle times. Prominent biopharmaceutical companies are actively adopting these digital tools to improve supply chain responsiveness. For example, Sanofi announced in May 2025 the launch of its third Digital Accelerator dedicated to digitizing its worldwide manufacturing and supply chain, aiming to cut the time to market for new drugs by as much as one year through these AI-powered initiatives.

Key Market Players

  • B. Braun Melsungen AG
  • Baxter International Inc.
  • Becton, Dickinson and Company
  • Schott AG
  • Aristopharma Ltd.
  • Vetter Pharma GmbH
  • Jubilant HollisterStier LLC
  • F. Hoffmann-La Roche Ltd
  • Novo Nordisk A/S

Report Scope

In this report, the Global Lyophilized Injectable Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Lyophilized Injectable Market, By Packaging

  • Single-Use Vials
  • Point-Of-Care Reconstitution
  • Specialty Packaging

Lyophilized Injectable Market, By Delivery

  • Prefilled Diluent Syringes
  • Proprietary Reconstitution Devices
  • Single-Step Devices
  • Multi-Step Devices

Lyophilized Injectable Market, By Indication

  • Autoimmune Diseases
  • Infectious Diseases
  • Metabolic Conditions
  • Others

Lyophilized Injectable Market, By End-User

  • Hospital Pharmacy
  • Retail Pharmacy
  • Others

Lyophilized Injectable Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Lyophilized Injectable Market.

Available Customizations:

Global Lyophilized Injectable Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Lyophilized Injectable Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Packaging (Single-Use Vials, Point-Of-Care Reconstitution, Specialty Packaging)
    • 5.2.2. By Delivery (Prefilled Diluent Syringes, Proprietary Reconstitution Devices, Single-Step Devices, Multi-Step Devices)
    • 5.2.3. By Indication (Autoimmune Diseases, Infectious Diseases, Metabolic Conditions, Others)
    • 5.2.4. By End-User (Hospital Pharmacy, Retail Pharmacy, Others)
    • 5.2.5. By Region
    • 5.2.6. By Company (2025)
  • 5.3. Market Map

6. North America Lyophilized Injectable Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Packaging
    • 6.2.2. By Delivery
    • 6.2.3. By Indication
    • 6.2.4. By End-User
    • 6.2.5. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Lyophilized Injectable Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Packaging
        • 6.3.1.2.2. By Delivery
        • 6.3.1.2.3. By Indication
        • 6.3.1.2.4. By End-User
    • 6.3.2. Canada Lyophilized Injectable Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Packaging
        • 6.3.2.2.2. By Delivery
        • 6.3.2.2.3. By Indication
        • 6.3.2.2.4. By End-User
    • 6.3.3. Mexico Lyophilized Injectable Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Packaging
        • 6.3.3.2.2. By Delivery
        • 6.3.3.2.3. By Indication
        • 6.3.3.2.4. By End-User

7. Europe Lyophilized Injectable Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Packaging
    • 7.2.2. By Delivery
    • 7.2.3. By Indication
    • 7.2.4. By End-User
    • 7.2.5. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Lyophilized Injectable Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Packaging
        • 7.3.1.2.2. By Delivery
        • 7.3.1.2.3. By Indication
        • 7.3.1.2.4. By End-User
    • 7.3.2. France Lyophilized Injectable Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Packaging
        • 7.3.2.2.2. By Delivery
        • 7.3.2.2.3. By Indication
        • 7.3.2.2.4. By End-User
    • 7.3.3. United Kingdom Lyophilized Injectable Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Packaging
        • 7.3.3.2.2. By Delivery
        • 7.3.3.2.3. By Indication
        • 7.3.3.2.4. By End-User
    • 7.3.4. Italy Lyophilized Injectable Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Packaging
        • 7.3.4.2.2. By Delivery
        • 7.3.4.2.3. By Indication
        • 7.3.4.2.4. By End-User
    • 7.3.5. Spain Lyophilized Injectable Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Packaging
        • 7.3.5.2.2. By Delivery
        • 7.3.5.2.3. By Indication
        • 7.3.5.2.4. By End-User

8. Asia Pacific Lyophilized Injectable Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Packaging
    • 8.2.2. By Delivery
    • 8.2.3. By Indication
    • 8.2.4. By End-User
    • 8.2.5. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Lyophilized Injectable Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Packaging
        • 8.3.1.2.2. By Delivery
        • 8.3.1.2.3. By Indication
        • 8.3.1.2.4. By End-User
    • 8.3.2. India Lyophilized Injectable Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Packaging
        • 8.3.2.2.2. By Delivery
        • 8.3.2.2.3. By Indication
        • 8.3.2.2.4. By End-User
    • 8.3.3. Japan Lyophilized Injectable Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Packaging
        • 8.3.3.2.2. By Delivery
        • 8.3.3.2.3. By Indication
        • 8.3.3.2.4. By End-User
    • 8.3.4. South Korea Lyophilized Injectable Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Packaging
        • 8.3.4.2.2. By Delivery
        • 8.3.4.2.3. By Indication
        • 8.3.4.2.4. By End-User
    • 8.3.5. Australia Lyophilized Injectable Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Packaging
        • 8.3.5.2.2. By Delivery
        • 8.3.5.2.3. By Indication
        • 8.3.5.2.4. By End-User

9. Middle East & Africa Lyophilized Injectable Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Packaging
    • 9.2.2. By Delivery
    • 9.2.3. By Indication
    • 9.2.4. By End-User
    • 9.2.5. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Lyophilized Injectable Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Packaging
        • 9.3.1.2.2. By Delivery
        • 9.3.1.2.3. By Indication
        • 9.3.1.2.4. By End-User
    • 9.3.2. UAE Lyophilized Injectable Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Packaging
        • 9.3.2.2.2. By Delivery
        • 9.3.2.2.3. By Indication
        • 9.3.2.2.4. By End-User
    • 9.3.3. South Africa Lyophilized Injectable Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Packaging
        • 9.3.3.2.2. By Delivery
        • 9.3.3.2.3. By Indication
        • 9.3.3.2.4. By End-User

10. South America Lyophilized Injectable Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Packaging
    • 10.2.2. By Delivery
    • 10.2.3. By Indication
    • 10.2.4. By End-User
    • 10.2.5. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Lyophilized Injectable Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Packaging
        • 10.3.1.2.2. By Delivery
        • 10.3.1.2.3. By Indication
        • 10.3.1.2.4. By End-User
    • 10.3.2. Colombia Lyophilized Injectable Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Packaging
        • 10.3.2.2.2. By Delivery
        • 10.3.2.2.3. By Indication
        • 10.3.2.2.4. By End-User
    • 10.3.3. Argentina Lyophilized Injectable Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Packaging
        • 10.3.3.2.2. By Delivery
        • 10.3.3.2.3. By Indication
        • 10.3.3.2.4. By End-User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Lyophilized Injectable Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. B. Braun Melsungen AG
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Baxter International Inc.
  • 15.3. Becton, Dickinson and Company
  • 15.4. Schott AG
  • 15.5. Aristopharma Ltd.
  • 15.6. Vetter Pharma GmbH
  • 15.7. Jubilant HollisterStier LLC
  • 15.8. F. Hoffmann-La Roche Ltd
  • 15.9. Novo Nordisk A/S

16. Strategic Recommendations

17. About Us & Disclaimer